Open AccessSafety and Effectiveness of Essential Phospholipids Paste in Patients with Non-alcoholic Fatty Liver Disease or Viral Hepatitis
Author(s) -
В. Т. Ивашкин,
И. В. Маев,
Chavdar S Pavlov,
M.V. Mayevskaya,
А А Самсонов,
Lyudmila K Palgova,
Kirill M Starostin
Publication year - 2021
Publication title -
pubmed central
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 28
eISSN - 2148-5607
DOI - 10.5152/tjg.2021.20294
Subject(s) - medicine , fatty liver , gastroenterology , viral hepatitis , liver disease , hepatitis , population , adverse effect , hepatitis c , viral load , disease , immunology , human immunodeficiency virus (hiv) , environmental health
Essential phospholipids (EPL) are used as adjuvant treatment in people with fatty liver disease and other chronic liver diseases. A new formulation of EPL paste was developed to improve patient compliance. The study was aimed to assess the safety, patient-reported outcomes, and impact on compliance of the new EPL paste formulation in patients with non-alcoholic fatty liver disease (NAFLD) or viral hepatitis.